Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
90Y-DOTATOC in Relapsed/Refractory DLBCL and MCL
NCT02488512Phase 2Terminated
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
- Start
- Dec 2016
- Primary completion
- Feb 2018
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
A Phase 2 trial of yttrium-90 edotreotide in diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), sponsored by Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori". Started Dec 2016; status: terminated.
02
Drugs
yttrium-90 edotreotide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT02488512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02488512.